Efficacy and Tolerability of Riluzole in Treatment Resistant Depression

This study is currently recruiting participants.
Verified January 2014 by Yale University
Sponsor:
Information provided by (Responsible Party):
Gerard Sanacora, Yale University
ClinicalTrials.gov Identifier:
NCT01204918
First received: September 16, 2010
Last updated: January 15, 2014
Last verified: January 2014

September 16, 2010
January 15, 2014
June 2011
May 2015   (final data collection date for primary outcome measure)
Change in Montgomery and Asberg Depression Rating Scale (MADRS) [ Time Frame: 8 weeks of therapy ] [ Designated as safety issue: No ]
This 10 item instrument is completed by the clinician by using a structured interview and defined anchor points, and aims to quantify the degree of depression over the past 7 days. The MADRS is a widely studied instrument for depression, and its reliability and validity are high. This instrument is administered at every study visit during the double-blind RCT, and at the screening, and baseline.
Same as current
Complete list of historical versions of study NCT01204918 on ClinicalTrials.gov Archive Site
  • Responders having at least a 50% improvement in MADRS compared to the baseline [ Time Frame: 8 weeks therapy ] [ Designated as safety issue: No ]
    Responders having at least a 50% improvement in MADRS compared to the baseline in the sequential parallel design
  • Systematic Assessment for Treatment Emergent Events (SAFTEE-SI) [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
    a commonly used instrument originally developed by NIMH and adapted into a self-report instrument. The version of the scale that we plan to use examines in a systematic fashion all possible treatment-emergent side effects and probes specific adverse symptoms, including suicidal thoughts and behaviors, and self-injurious behavior.
Same as current
Not Provided
Not Provided
 
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression

This study aims to examine the antidepressant efficacy of riluzole, employing a randomized, double-blind, placebo-controlled, adjunctive trial in treatment-resistant major depressive disorder (TRD).

This study aims to examine the antidepressant efficacy of riluzole, employing a randomized, double-blind, placebo-controlled, 8 week trial of adjunctive trial in treatment-resistant major depressive disorder (TRD). Preclinical studies have shown riluzole to modulate Glu release and clearance, and to have potent neuroprotective properties, promoting neuro-resiliency. Other preclinical data now also show the drug to have antidepressant-like effects in rodent models used to screen for antidepressant activity. In addition, several small open-label clinical studies further suggest riluzole has antidepressant and anxiolytic properties, even in patients who do not respond to standard monoaminergic antidepressant and anxiolytic medications.

Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Depression
  • Drug: Riluzole
    Riluzole 100mg PO for up to 8 weeks
    Other Name: Rilutek
  • Drug: placebo
    placebo
  • Experimental: Riluzole addition to SSRI antidepressant
    Riluzole 100mg added to ongoing SSRI or SNRI antidepressant
    Intervention: Drug: Riluzole
  • Placebo Comparator: Placebo addition to standard SSRI antidepressant
    Placebo will be added to ongoing SSRI or SNRI antidepressant treatment
    Intervention: Drug: placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
150
August 2015
May 2015   (final data collection date for primary outcome measure)

Group A inclusion/exclusion

Inclusion Criteria:

  1. Age 18-65
  2. Written informed consent
  3. Meets DSM-IV criteria (by Structured Clinical Interview for DSM-IV - SCID-I/P) for MDD, current
  4. Inventory of Depressive Symptomatology - Self-Rated (IDS-SR30) score of > 20 at screening, baseline and start of double-blind phase (Phase 2)
  5. May have a history of failure to respond to up to two FDA-approved antidepressants at adequate doses during the current episode for at least 8 weeks, and for inclusion into the Phase 2 subjects must have failed the 8-week prospective citalopram treatment.
  6. Montgomery Asberg Depression Rating Scale (MADRS) score of 18 or higher at baseline and start of Phase 2.

Exclusion Criteria:

  1. Pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (to include oral contraceptive or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, or partner with vasectomy)
  2. Patients who no longer meet DSM-IV criteria for MDD during the baseline visit
  3. Patients who demonstrate > 50% decrease in depressive symptoms as reflected by the IDS-SR total score from screen to baseline
  4. Serious suicide or homicide risk, as assessed by evaluating clinician A serious suicide risk will be considered an inability to control suicide attempts, imminent risk of suicide in the investigator's judgment, or a history of serious suicidal behavior, which is defined using the Columbia-Suicide Severity Rating Scale (C-SSRS) as either (1) one or more actual suicide attempts in the 3 years before study entry with the lethality rated at 3 or higher, or (2) one or more interrupted suicide attempts with a potential lethality judged to result in serious injury or death.
  5. Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease
  6. The following DSM-IV diagnoses: substance use disorders active within the last six months, any bipolar disorder (current or past), any psychotic disorder (current or past)
  7. History of a seizure disorder or clinical evidence of untreated hypothyroidism
  8. Patients requiring excluded medications (see Table 3 for details)
  9. Psychotic features in the current episode or a history of psychotic features, as assessed by SCID
  10. Any investigational psychotropic drug within the last 3 months
  11. Have failed 3 or more adequate antidepressant trials during the current Major Depressive Episode by MGH-ATRQ criteria.
  12. Patients with a history of antidepressant-induced hypomania.
  13. Patients with any evidence of clinically significant liver abnormalities, or any liver transaminase level >1.5 X ULN at initial screening, or >5 x ULN during Phase 2 treatment.
  14. Axis II personality disorders that are the primary purpose of treatment, or would interfere with a patient's safety or compliance.
  15. Patients currently being treated for a respiratory disorder (including asthma or COPD)
  16. Any subject who scores a 5 or higher on item #10 of the MADRS

Group B inclusion/exclusion

Inclusion criteria:

  1. Age 18-65
  2. Written informed consent
  3. Meets DSM-IV criteria (by Structured Clinical Interview for DSM-IV - SCID-I/P) for MDD, current
  4. Inventory of Depressive Symptomatology - Self-Rated (IDS-SR30) score of > 20 at screening and baseline visits, that is at the start of Phase 2
  5. Has a history of failure to respond to 1, 2, or 3 FDA-approved antidepressants at adequate doses during the current episode for at least 8 weeks, as defined by the MGH Antidepressant Treatment Response Questionnaire (MGH-ATRQ), and must be currently on the failed SSRI for at least 8 weeks and on a stable dose for at least 4 weeks.
  6. Montgomery Asberg Depression Rating Scale (MADRS) score of 18 or higher at baseline and start of Phase 2.

Exclusion Criteria

  1. Pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (to include oral contraceptive or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, or partner with vasectomy)
  2. Patients who no longer meet DSM-IV criteria for MDD during the baseline visit
  3. Serious suicide or homicide risk, as assessed by evaluating clinician A serious suicide risk will be considered an inability to control suicide attempts, imminent risk of suicide in the investigator's judgment, or a history of serious suicidal behavior, which is defined using the Columbia-Suicide Severity Rating Scale (C-SSRS) as either (1) one or more actual suicide attempts in the 3 years before study entry with the lethality rated at 3 or higher, or (2) one or more interrupted suicide attempts with a potential lethality judged to result in serious injury or death.
  4. Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease
  5. The following DSM-IV diagnoses: substance use disorders active within the last six months, any bipolar disorder (current or past), any psychotic disorder (current or past)
  6. History of a seizure disorder or clinical evidence of untreated hypothyroidism;
  7. Patients requiring excluded medications (see Table 3 for details)
  8. Psychotic features in the current episode or a history of psychotic features, as assessed by SCID
  9. Any investigational psychotropic drug within the last 3 months
  10. Have failed 3 or more adequate antidepressant trials during the current Major Depressive Episode by MGH-ATRQ criteria.
  11. Patients with a history of antidepressant-induced hypomania.
  12. Patients with any evidence of clinically significant liver abnormalities, or any liver transaminase level >2 X ULN at initial screening, or >5 x ULN during Phase 2 treatment.
  13. Axis II personality disorders that are the primary purpose of treatment, or would interfere with a patients safety or compliance.
  14. Patients currently being treated for a respiratory disorder (including asthma or COPD)
  15. Any subject who scores a 5 or higher on item #10 of the MADRS
Both
18 Years to 65 Years
No
Not Provided
United States
 
NCT01204918
HIC#0903004917
Yes
Gerard Sanacora, Yale University
Yale University
Not Provided
Principal Investigator: Gerard Sanacora, MD PhD Yale University
Principal Investigator: Maurizio Fava, MD Massachusettes General Hospital
Principal Investigator: Sanjay Matthew, MD Baylor College of Medicine
Principal Investigator: Carlos Zarate, MD National Institute of Mental Health (NIMH)
Yale University
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP